Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
4(44%)
Results Posted
80%(4 trials)

Phase Distribution

Ph phase_3
1
11%
Ph phase_2
2
22%
Ph phase_1
6
67%

Phase Distribution

6

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
6(66.7%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

9

all time

Status Distribution
Active(4)
Completed(5)

Detailed Status

Completed5
Active, not recruiting3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (66.7%)
Phase 22 (22.2%)
Phase 31 (11.1%)

Trials by Status

recruiting111%
active_not_recruiting333%
completed556%

Recent Activity

4 active trials
Showing 5 of 9
recruitingphase_2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
completedphase_1

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

NCT04072952
active_not_recruitingphase_3

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623
active_not_recruitingphase_1

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

NCT05573555
active_not_recruitingphase_1

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

NCT05548127
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01042379Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting
NCT04072952Phase 1

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Completed
NCT05654623Phase 3

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Active Not Recruiting
NCT05573555Phase 1

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

Active Not Recruiting
NCT05548127Phase 1

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

Active Not Recruiting
NCT05549505Phase 2

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

Completed
NCT05732428Phase 1

A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China

Completed
NCT05673889Phase 1

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults

Completed
NCT05652660Phase 1

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9